Zealand Pharma A/S (ZEAL.CO)
DKK 408.6
(0.64%)
DKK 408.6
(0.64%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 102.57 Million DKK | -76.08% |
| 2022 | 428.74 Million DKK | -44.5% |
| 2021 | 772.53 Million DKK | 612.3% |
| 2020 | 108.45 Million DKK | 38.93% |
| 2019 | 78.06 Million DKK | 0.0% |
| 2018 | - DKK | -100.0% |
| 2017 | 132.98 Million DKK | -59.56% |
| 2016 | 328.87 Million DKK | 5.09% |
| 2015 | 312.95 Million DKK | 17.14% |
| 2014 | 267.17 Million DKK | 0.0% |
| 2013 | - DKK | 0.0% |
| 2012 | - DKK | 0.0% |
| 2011 | - DKK | 0.0% |
| 2010 | - DKK | 0.0% |
| 2009 | - DKK | 0.0% |
| 2008 | - DKK | -100.0% |
| 2007 | 1.12 Million DKK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 276.79 Million DKK | 1.54% |
| 2024 Q1 | 272.59 Million DKK | 0.0% |
| 2023 FY | 102.57 Million DKK | -76.08% |
| 2023 Q2 | 102.07 Million DKK | -79.49% |
| 2023 Q3 | 101.08 Million DKK | -0.97% |
| 2023 Q4 | 102.57 Million DKK | 1.47% |
| 2023 Q1 | 497.72 Million DKK | 16.09% |
| 2022 Q1 | 776.98 Million DKK | 0.58% |
| 2022 Q4 | 428.74 Million DKK | -10.83% |
| 2022 Q2 | 471.59 Million DKK | -39.3% |
| 2022 Q3 | 480.81 Million DKK | 1.95% |
| 2022 FY | 428.74 Million DKK | -44.5% |
| 2021 Q2 | 128.76 Million DKK | 12.69% |
| 2021 Q3 | 126.5 Million DKK | -1.76% |
| 2021 Q1 | 114.26 Million DKK | 5.36% |
| 2021 Q4 | 772.53 Million DKK | 510.67% |
| 2021 FY | 772.53 Million DKK | 612.3% |
| 2020 Q3 | 119.29 Million DKK | -2.7% |
| 2020 Q1 | 91.23 Million DKK | 16.86% |
| 2020 Q2 | 122.59 Million DKK | 34.38% |
| 2020 FY | 108.45 Million DKK | 38.93% |
| 2020 Q4 | 108.45 Million DKK | -9.08% |
| 2019 Q2 | - DKK | 0.0% |
| 2019 FY | 78.06 Million DKK | 0.0% |
| 2019 Q1 | - DKK | 0.0% |
| 2019 Q3 | - DKK | 0.0% |
| 2019 Q4 | 78.06 Million DKK | 0.0% |
| 2018 Q4 | - DKK | 0.0% |
| 2018 Q3 | - DKK | -100.0% |
| 2018 Q2 | 143.43 Million DKK | 9.61% |
| 2018 Q1 | 130.86 Million DKK | -1.6% |
| 2018 FY | - DKK | -100.0% |
| 2017 FY | 132.98 Million DKK | -59.56% |
| 2017 Q1 | 126.52 Million DKK | -61.53% |
| 2017 Q3 | 125.37 Million DKK | -11.95% |
| 2017 Q4 | 132.98 Million DKK | 6.07% |
| 2017 Q2 | 142.39 Million DKK | 12.54% |
| 2016 Q2 | 297.11 Million DKK | -1.59% |
| 2016 FY | 328.87 Million DKK | 5.09% |
| 2016 Q1 | 301.93 Million DKK | -3.52% |
| 2016 Q4 | 328.87 Million DKK | 9.57% |
| 2016 Q3 | 300.14 Million DKK | 1.02% |
| 2015 Q3 | 328.23 Million DKK | 10.85% |
| 2015 Q4 | 312.95 Million DKK | -4.66% |
| 2015 FY | 312.95 Million DKK | 17.14% |
| 2015 Q1 | 303.68 Million DKK | 13.67% |
| 2015 Q2 | 296.11 Million DKK | -2.49% |
| 2014 Q2 | - DKK | 0.0% |
| 2014 Q4 | 267.17 Million DKK | 0.0% |
| 2014 Q3 | - DKK | 0.0% |
| 2014 FY | 267.17 Million DKK | 0.0% |
| 2014 Q1 | - DKK | 0.0% |
| 2013 FY | - DKK | 0.0% |
| 2013 Q2 | - DKK | 0.0% |
| 2013 Q4 | - DKK | 0.0% |
| 2013 Q1 | - DKK | 0.0% |
| 2013 Q3 | - DKK | 0.0% |
| 2012 FY | - DKK | 0.0% |
| 2012 Q3 | - DKK | 0.0% |
| 2012 Q4 | - DKK | 0.0% |
| 2012 Q2 | - DKK | 0.0% |
| 2012 Q1 | - DKK | 0.0% |
| 2011 FY | - DKK | 0.0% |
| 2011 Q3 | - DKK | 0.0% |
| 2011 Q4 | - DKK | 0.0% |
| 2011 Q1 | - DKK | 0.0% |
| 2011 Q2 | - DKK | 0.0% |
| 2010 Q4 | - DKK | 0.0% |
| 2010 FY | - DKK | 0.0% |
| 2009 FY | - DKK | 0.0% |
| 2008 FY | - DKK | -100.0% |
| 2007 FY | 1.12 Million DKK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ALK-Abelló A/S | 439 Million DKK | 76.634% |
| Bavarian Nordic A/S | 15.13 Million DKK | -577.734% |
| Genmab A/S | 680 Million DKK | 84.915% |
| Gubra A/S | 60.68 Million DKK | -69.029% |
| Novo Nordisk A/S | 20.52 Billion DKK | 99.5% |
| Orphazyme A/S | - DKK | -Infinity% |
| Pharma Equity Group A/S | 8.07 Million DKK | -1170.751% |